The invention relates to novel inhibitors of the PIKFYVE, a phosphoinositide kinase, useful for the treatment of diseases or disorders characterized by dysregulation of phosphoinositide mediated signal transduction pathways, including hyperproliferative diseases, autoimmune diseases, Crohn's disease, psoriasis, neurological diseases, diabetes, corneal fleck dystrophy, and viral infection (including HIV, Ebola, and coronavirus infections). The invention further relates to pharmaceutical compositions comprising PIKFYVE inhibitors and methods of treatment of such diseases and disorders.
该发明涉及一种新型
PIKFYVE
抑制剂,它是一种
磷脂酰肌醇激酶,可用于治疗由于
磷脂酰肌醇介导的
信号转导通路失调所导致的疾病或障碍,包括增殖过度性疾病、自身免疫性疾病、克罗恩病、
银屑病、神经系统疾病、糖尿病、角膜斑点萎缩症和病毒感染(包括HIV、埃博拉和冠状病毒感染)。该发明还涉及包含
PIKFYVE
抑制剂的制药组合物和治疗上述疾病和障碍的方法。